Mode
Text Size
Log in / Sign up

Nanophotothermal systems using chitosan and hyaluronic acid provide real-time monitoring and multi-functional drug deliveryNew nanotech systems combine cancer treatment and real-time monitoring

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that nanophotothermal systems using chitosan and hyaluronic acid offer multi-functional drug delivery and real-time monitoring.

This narrative review explores the development and application of nanophotothermal systems (NPTSs) composed of chitosan (CS) and hyaluronic acid (HA) in cancer treatment. The scope of the review focuses on the integration of therapeutic functionalities with diagnostic imaging modalities, including magnetic resonance, fluorescence, and photoacoustic imaging. These integrated systems are intended to provide real-time monitoring of treatment response.

The authors synthesize the advantages of NPTSs, specifically their ability to serve as multifunctional platforms for drug delivery and diagnostic imaging. By combining these capabilities, the systems aim to improve the precision of cancer interventions. The review highlights the potential for these systems to facilitate the transition of photothermal therapy into clinical practice.

Several limitations to clinical translation are identified, including concerns regarding toxicity, biodegradability, scalability, and the need for standardization. Furthermore, the review notes that regulatory approval remains a significant hurdle for these technologies. Clinical application is currently limited by these technical and regulatory barriers.

How this fits prior evidence

This review addresses a gap in the current evidence regarding multifunctional delivery systems. While prior coverage noted that tumor-activated prodrug nanoparticles improve delivery specificity and remodel the immune microenvironment, this review specifically explores the integration of nanophotothermal systems with real-time diagnostic imaging to monitor treatment response.

Treating cancer often requires a way to see what is happening inside the body while delivering medicine. New nanophotothermal systems (NPTSs) aim to do both at once. These systems use materials like chitosan and hyaluronic acid to create a multi-purpose tool for doctors.

These systems work by combining treatment with diagnostic imaging. This means doctors can use techniques like magnetic resonance or fluorescence to monitor how a patient responds to treatment in real time. This dual role helps make the treatment more precise and easier to track as it happens.

While these systems show promise for drug delivery and better monitoring, they are not ready for everyday use yet. Researchers still need to solve hurdles like making the materials safe for the body, ensuring they break down naturally, and getting them approved by regulators. These steps are necessary to move the technology from the lab to the clinic.

What this means for you:
Nanophotothermal systems can provide both cancer treatment and real-time imaging in one tool.

Common questions

What makes these nanophotothermal systems different?

These systems are unique because they combine two jobs into one. They can deliver medicine to treat cancer while also providing real-time monitoring through imaging techniques like magnetic resonance or fluorescence. This allows doctors to see how the treatment is working as it happens.

What materials are used in these systems?

The systems use specific materials called chitosan and hyaluronic acid. These are used to create the nanophotothermal systems that help with drug delivery and diagnostic imaging for cancer patients.

Are these treatments available for patients now?

Not yet. While the technology shows promise for drug delivery and monitoring, it faces several hurdles before it can be used in clinics. These include issues with safety, how the materials break down in the body, and getting official regulatory approval.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Conventional protocols for cancer treatment are usually accompanied by serious limitations, which can be addressed using innovative, minimally invasive methods, such as photothermal therapy (PTT). But, using this method as a standalone therapy is usually accompanied by uneven heat distribution within tumor tissues, and the risk of cancer recurrence. Integrating PTT with complementary therapeutic modalities can help prevent these issues. The development of nanophotothermal systems (NPTSs) as multipurpose, multimodal platforms for smart drug delivery has greatly broadened the therapeutic landscape of cancer treatment. Additionally, recent developments in bio-based and biocompatible nanomaterials have further expanded the potential of NPTSs in clinical applications. Furthermore, NPTSs combine therapeutic functionalities and diagnostic imaging, i.e., tracking modalities, such as photoacoustic, magnetic resonance, or fluorescence imaging, to provide real-time monitoring of drug delivery and treatment response. Translation of preclinical trials into clinical applications for these systems remains challenging due to issues such as toxicity, biodegradability, scalability, standardization, and regulatory approval. This narrative review analyzes two of the most versatile natural polysaccharides, chitosan (CS) and hyaluronic acid (HA), which have complementary physicochemical and biological properties. Covering the advantages of CS and HA for the application in multifuntional and multimodal nanophotothermal systems, their complementary effects, as well as their functional implications in therapeutic settings, this work aims to create a framework that will serve as a basis for further research in optimizing the design of multifunctional drug-delivery nanosystems, and at the same time, facilitate the transition of photothermal therapy from the bench to clinical use.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.